Comparison of Overall Survival Associated with Lenalidomide plus Dexamethasone and Bortezomib plus Dexamethasone Among Relapsed / Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

被引：0
|
作者：
Nooka, Ajay
Voorhees, Peter M.
Kumar, Shaji K.
Mehra, Maneesha
Lam, Annette
Slavcev, Mary
Potluri, Ravi
Dasgupta, Anandaroop
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3094
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
    Richardson, Paul G.
    Xie, Wanling
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Lonial, Sagar
    Raje, Noopur S.
    Alsina, Melissa
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Mazumder, Amitabha
    Vesole, David H.
    Kaufman, Jonathan L.
    Colson, Kathleen
    McKenney, Mary
    Lunde, Laura E.
    Feather, John
    Maglio, Michelle E.
    Warren, Diane
    Francis, Dixil
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Mitsiades, Constantine S.
    Weller, Edie
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (10) : 1461 - 1469
  • [22] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis
    Stork, Martin
    Spicka, Ivan
    Radocha, Jakub
    Minarik, Jiri
    Jelinek, Tomas
    Jungova, Alexandra
    Pavlicek, Petr
    Pospisilova, Lenka
    Sedlak, Frantisek
    Straub, Jan
    Pika, Tomas
    Knechtova, Zdenka
    Fidrichova, Anna
    Boichuk, Ivanna
    Sevcikova, Sabina
    Maisnar, Vladimir
    Hajek, Roman
    Pour, Ludek
    ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1501 - 1511
  • [23] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
    Martin Stork
    Ivan Spicka
    Jakub Radocha
    Jiri Minarik
    Tomas Jelinek
    Alexandra Jungova
    Petr Pavlicek
    Lenka Pospisilova
    Frantisek Sedlak
    Jan Straub
    Tomas Pika
    Zdenka Knechtova
    Anna Fidrichova
    Ivanna Boichuk
    Sabina Sevcikova
    Vladimir Maisnar
    Roman Hajek
    Ludek Pour
    Annals of Hematology, 2023, 102 : 1501 - 1511
  • [24] Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
    Harousseau, Jean-Luc
    Dimopoulos, Meletios A.
    Wang, Michael
    Corso, Alessandro
    Chen, Christine
    Attal, Michel
    Spencer, Andrew
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome B.
    Knight, Robert D.
    Weber, Donna M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (10): : 1738 - 1744
  • [25] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
    Ziff, M.
    Cheesman, S.
    Kyriakou, C.
    Mehta, A.
    Papanikolaou, X.
    Rabin, N.
    Wechalekar, A.
    Yong, K.
    Popat, R.
    HAEMATOLOGICA, 2017, 102 : 786 - 787
  • [26] Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma
    不详
    FORMULARY, 2008, 43 (02) : 79 - 80
  • [27] Efficacy of lenalidomide plus dexamethasone in relapsed/refractory multiple myeloma: A systematic review
    Tandy, Fenia
    Hadisurya, Audrey
    Suciningtias, Marlyn
    Chrystelle, Celine
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2022, 33 : S489 - S489
  • [28] Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
    Chen, Christine
    Reece, Donna E.
    Siegel, David
    Niesvizky, Ruben
    Boccia, Ralph V.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Richardson, Paul
    Matous, Jeffrey
    Kumar, Shaji
    Bahlis, Nizar J.
    Alsina, Melissa
    Vescio, Robert
    Coutre, Steven E.
    Pietronigro, Dennis
    Knight, Robert D.
    Zeldis, Jerome B.
    Rajkumar, Vincent
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (02) : 164 - 170
  • [29] Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
    San-Miguel, Jesus F.
    Hungria, Vania T. M.
    Yoon, Sung-Soo
    Beksac, Meral
    Dimopoulos, Meletios Athanasios
    Elghandour, Ashraf
    Jedrzejczak, Wieslaw Wiktor
    Guenther, Andreas
    Nakorn, Thanyaphong Na
    Siritanaratkul, Noppadol
    Corradini, Paolo
    Chuncharunee, Suporn
    Lee, Je-Jung
    Schlossman, Robert L.
    Shelekhova, Tatiana
    Yong, Kwee
    Tan, Daryl
    Numbenjapon, Tontanai
    Cavenagh, Jamie D.
    Hou, Jian
    LeBlanc, Richard
    Nahi, Hareth
    Qiu, Lugui
    Salwender, Hans
    Pulini, Stefano
    Moreau, Philippe
    Warzocha, Krzysztof
    White, Darrell
    Blade, Joan
    Chen, WenMing
    de la Rubia, Javier
    Gimsing, Peter
    Lonial, Sagar
    Kaufman, Jonathan L.
    Ocio, Enrique M.
    Veskovski, Ljupco
    Sohn, Sang Kyun
    Wang, Ming-Chung
    Lee, Jae Hoon
    Einsele, Hermann
    Sopala, Monika
    Corrado, Claudia
    Bengoudifa, Bourras-Rezki
    Binlich, Florence
    Richardson, Paul G.
    LANCET ONCOLOGY, 2014, 15 (11): : 1195 - 1206
  • [30] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
12345